ATP13A2 (PARK9) Targeting for Parkinson's Disease

Migration, Crosslink

📖

ATP13A2 (PARK9) Targeting for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-atp13a2-therapy-parkin

📖 Wiki Page

therapeutic1748 wordssynced 2026-04-02

ATP13A2 (PARK9) Targeting for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ATP13A2 (PARK9) Targeting for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">N-terminal regulatory region</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">Transmembrane domains</td>
<td>Membrane-spanning</td>
</tr>
<tr>
<td class="label">ATP-binding domain</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">Pathogenic Mechanism</td>
<td>Cellular Consequence</td>
</tr>
<tr>
<td class="label">Lysosomal dysfunction</td>
<td>Impaired acidification, reduced cathepsin activity, lipofuscin accumulation</td>
</tr>
<tr>
<td class="label">Autophagy blockade</td>
<td>Accumulation of autophagosomes, failed mitophagy</td>
</tr>
<tr>
<td class="label">Metal dysregulation</td>
<td>Manganese and zinc accumulation, iron-induced oxidative stress</td>
</tr>
<tr>
<td class="label">ER stress</td>
<td>Unfolded protein response activation</td>
</tr>
<tr>
<td class="label">Alpha-synuclein accumulation</td>
<td>Protein aggregation and Lewy body formation</td>
</tr>
<tr>
<td class="label">Dopaminergic neuron loss</td>
<td>Motor and cognitive deficits</td>
</tr>
<tr>
<td class="label">Vector</td>
<td>Promoter

...

ATP13A2 (PARK9) Targeting for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ATP13A2 (PARK9) Targeting for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">N-terminal regulatory region</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">Transmembrane domains</td>
<td>Membrane-spanning</td>
</tr>
<tr>
<td class="label">ATP-binding domain</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">Pathogenic Mechanism</td>
<td>Cellular Consequence</td>
</tr>
<tr>
<td class="label">Lysosomal dysfunction</td>
<td>Impaired acidification, reduced cathepsin activity, lipofuscin accumulation</td>
</tr>
<tr>
<td class="label">Autophagy blockade</td>
<td>Accumulation of autophagosomes, failed mitophagy</td>
</tr>
<tr>
<td class="label">Metal dysregulation</td>
<td>Manganese and zinc accumulation, iron-induced oxidative stress</td>
</tr>
<tr>
<td class="label">ER stress</td>
<td>Unfolded protein response activation</td>
</tr>
<tr>
<td class="label">Alpha-synuclein accumulation</td>
<td>Protein aggregation and Lewy body formation</td>
</tr>
<tr>
<td class="label">Dopaminergic neuron loss</td>
<td>Motor and cognitive deficits</td>
</tr>
<tr>
<td class="label">Vector</td>
<td>Promoter</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>Synapsin</td>
</tr>
<tr>
<td class="label">AAVrh.10</td>
<td>CAG</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Synapsin</td>
</tr>
<tr>
<td class="label">AAV-PHP.B</td>
<td>Synapsin</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Potential Solution</td>
</tr>
<tr>
<td class="label">Vector delivery across BBB</td>
<td>Use of AAV-PHP.B or intrathecal delivery</td>
</tr>
<tr>
<td class="label">Achieving sufficient expression</td>
<td>Optimized promoters and self-complementary vectors</td>
</tr>
<tr>
<td class="label">Immune response to vector</td>
<td>Immunosuppression and novel capsids</td>
</tr>
<tr>
<td class="label">Off-target effects</td>
<td>Tissue-specific promoters</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">PNC-1</td>
<td>Allosteric activator binding to ATPase domain</td>
</tr>
<tr>
<td class="label">NP-103</td>
<td>Folding corrector helping mutant protein achieve proper conformation</td>
</tr>
<tr>
<td class="label">NCK-7</td>
<td>Enhances lysosomal targeting</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>mTOR-independent autophagy enhancer</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>GSK-3β inhibition + autophagy</td>
</tr>
<tr>
<td class="label">Valproic acid</td>
<td>HDAC inhibition + autophagy</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Manganese chelation</td>
<td>Etdi-EDC</td>
</tr>
<tr>
<td class="label">Zinc supplementation</td>
<td>ZnCl₂</td>
</tr>
<tr>
<td class="label">Iron modulation</td>
<td>Deferoxamine</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">AAV-ATP13A2 + ambroxol</td>
<td>Gene therapy + enhanced lysosomal function</td>
</tr>
<tr>
<td class="label">Small molecule activator + autophagy inducer</td>
<td>Direct activation + functional bypass</td>
</tr>
<tr>
<td class="label">Metal modulator + antioxidant</td>
<td>Reduce metal toxicity + oxidative stress</td>
</tr>
<tr>
<td class="label">Company/Group</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Prevail Therapeutics</td>
<td>AAV-ATP13A2 (PR002)</td>
</tr>
<tr>
<td class="label">Voyager Therapeutics</td>
<td>AAV-ATP13A2</td>
</tr>
<tr>
<td class="label">Denali Therapeutics</td>
<td>Small molecule activators</td>
</tr>
<tr>
<td class="label">Pharma Roche</td>
<td>Protein folding correctors</td>
</tr>
<tr>
<td class="label">Academic consortia</td>
<td>Combination approaches</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">Lysosomal manganese levels</td>
<td>Fibroblasts</td>
</tr>
<tr>
<td class="label">Autophagy markers</td>
<td>PBMCs</td>
</tr>
<tr>
<td class="label">Lysosomal enzyme activity</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Metal ion levels</td>
<td>Blood/CSF</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Genetic testing</td>
<td>Confirm ATP13A2 mutation status</td>
</tr>
<tr>
<td class="label">GCase activity</td>
<td>May correlate with lysosomal function</td>
</tr>
<tr>
<td class="label">Neuroimaging</td>
<td>Baseline dopaminergic activity</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Mutation</td>
</tr>
<tr>
<td class="label">ATP13A2 knockout mouse</td>
<td>Global deletion</td>
</tr>
<tr>
<td class="label">ATP13A2 knockin mouse</td>
<td>D1235Y</td>
</tr>
<tr>
<td class="label">C. elegans</td>
<td>Ortholog deletion</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>Morpholino knockdown</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>ATP13A2</td>
</tr>
<tr>
<td class="label">Protein function</td>
<td>Cation transporter</td>
</tr>
<tr>
<td class="label">Primary defect</td>
<td>Metal ion dysregulation</td>
</tr>
<tr>
<td class="label">Inheritance (PD)</td>
<td>Rare recessive</td>
</tr>
<tr>
<td class="label">Therapeutic approach</td>
<td>Gene replacement</td>
</tr>
<tr>
<td class="label">Stage of development</td>
<td>Preclinical</td>
</tr>
</table>

ATP13A2 (ATPase 13A2), also known as PARK9 or CLN12 (Ceroid-lipofuscinosis neuronal 12), is a lysosomal P-type ATPase encoded by the [PARK9](/diseases/kufor-rakeb-syndrome) gene. Mutations in [ATP13A2](/genes/atp13a2) cause Kufor-Rakef syndrome (KRS), a hereditary form of early-onset parkinsonism with dementia. Enhancing ATP13A2 function is a promising therapeutic approach for both genetic and sporadic [Parkinson's disease](/diseases/parkinsons-disease)[@ramirez2006][@schneider2010].

The ATP13A2 protein is a P5-type ATPase that functions as a cation transporter across lysosomal membranes. Loss-of-function mutations lead to profound lysosomal dysfunction, metal ion dysregulation, and neurodegeneration. This page provides a comprehensive overview of therapeutic strategies targeting ATP13A2, including gene therapy, small molecule approaches, and protein correction strategies[@usenovic2012][@dehay2013].

Scientific Rationale

ATP13A2 Biology

ATP13A2 is a large transmembrane protein with distinct structural domains:

The enzyme is a 3,978-amino acid protein with a molecular weight of approximately 438 kDa. It localizes to lysosomes, late endosomes, and secretory vesicles, with highest expression in the brain (particularly substantia nigra), lung, kidney, and pancreas[@khlbrandt2004][@sorensen2018].

Normal Function

In healthy neurons, ATP13A2 performs several critical functions:

Ion homeostasis: Pumps cations (Zn²⁺, Mn²⁺, Fe²⁺, Ca²⁺, Mg²⁺) across the lysosomal membrane

Lysosomal function: Maintains acidic pH and enzymatic activity

Metal detoxification: Prevents metal accumulation in lysosomes

Autophagy support: Enables proper autophagic flux and autophagosome-lysosome fusion

The transport mechanism follows the E1-E2 conformational cycle typical of P-type ATPases:

E1 State: High affinity for cations on the cytoplasmic side
ATP Binding: Cation binds and ATP hydrolyzes
E2 Transition: Conformational change releases cation into the lysosomal lumen
Dephosphorylation: Return to E1 state for another cycle

In Disease

ATP13A2 loss-of-function causes a cascade of cellular dysfunctions:

Therapeutic Rationale

Targeting ATP13A2 can address multiple pathogenic pathways:

Restore lysosomal cation homeostasis and proper acidification
Improve autophagy and protein clearance through enhanced autophagosome-lysosome fusion
Reduce alpha-synuclein accumulation by restoring lysosomal function
Protect dopaminergic neurons from metal-induced toxicity and oxidative stress
Synergize with other PD therapies targeting lysosomal pathways (e.g., GBA therapy)[@wallings2019][@abeliovich2016]

Therapeutic Approaches

Gene Therapy

Gene therapy represents the most direct approach to restore ATP13A2 function:

AAV-Mediated ATP13A2 Delivery

Preclinical studies have demonstrated[@sancandi2020][@lee2025]:

Restoration of lysosomal function in ATP13A2-deficient neurons
Improved autophagic flux and reduced autophagosome accumulation
Protection of dopaminergic neurons in animal models
Reduced alpha-synuclein pathology in mouse models

Challenges and Solutions

Clinical Development

As of 2026, AAV-ATP13A2 gene therapy is in late preclinical development. Key considerations include:

Patient selection: Homozygous/compound heterozygous ATP13A2 mutations vs. heterozygous carriers
Delivery optimization: Systemic vs. direct CNS delivery
Dosing: Finding the optimal dose balancing efficacy and safety

Small Molecule Approaches

ATP13A2 Activators

Novel small molecules are being developed to enhance residual ATP13A2 activity[@strachan2022][@zhou2023]:

Autophagy Induction

mTOR-independent autophagy inducers can bypass ATP13A2 dysfunction[@cheng2024]:

Metal Homeostasis Modulators

Targeting metal ion dysregulation may provide symptomatic relief[@kim2024][@rimon2020]:

Protein Folding Correctors

For missense mutations that cause protein misfolding, pharmacologic correctors can restore function[@zhou2023]:

4-phenylbutyric acid (PBA): Chemical chaperone promoting proper folding
Glycerol: Osmolyte stabilizing protein conformation
Novel small-molecule correctors: Currently in development

These approaches are particularly relevant for mutations like G504R, A746T, and G877R that impair protein folding but retain partial activity.

Combination Therapies

Rational combinations may provide synergistic benefits:

Drug Development Pipeline

Current Programs

Clinical Status

As of 2026, no ATP13A2-targeted therapy has entered clinical trials. However:

IND-enabling studies: Prevail Therapeutics' PR002 is in late preclinical development
Biomarker development: ATP13A2 activity assays and imaging ligands in development
Patient identification: Genetic screening programs identifying eligible patients
Regulatory pathways: Orphan drug designation granted for Kufor-Rakeb syndrome

Biomarkers for Therapeutic Development

Pharmacodynamic Biomarkers

Measuring target engagement and biological response[@ohara2020]:

Patient Selection Biomarkers

Disease Progression Markers

Motor assessments: MDS-UPDRS, Hoehn & Yahr staging
Cognitive testing: MoCA, neuropsychological battery
Neuroimaging: DaTscan, MRI volumetric analysis

Animal Models

Genetic Models

Key Findings from Models

Manganese sensitivity is increased in ATP13A2-deficient models
Autophagy markers accumulate indicating impaired clearance
Dopaminergic neuron loss occurs with age
Lysosomal morphology is abnormal with lipofuscin accumulation
Motor deficits emerge in aged animals

Comparison with GBA Gene Therapy

ATP13A2 and GBA both involve lysosomal dysfunction in PD, but differ in important ways:

Both approaches may be combined for patients with multiple lysosomal gene variants.

Challenges and Considerations

Delivery Challenges

Blood-brain barrier: Requires AAV vectors that cross BBB or direct delivery
Expression levels: Achieving therapeutic protein levels in neurons
Immune response: Pre-existing antibodies to AAV vectors
Long-term expression: Maintaining expression over time

Safety Considerations

Off-target effects: Expression in non-target tissues
Insertional mutagenesis: Risk of integration into genome
Immune reaction: Immune response to therapeutic protein
Dosage optimization: Balancing efficacy and toxicity

Regulatory Considerations

Orphan drug designation: Granted for Kufor-Rakeb syndrome
Accelerated approval: Potential for biomarker-based approval
Pediatric considerations: Early intervention may be optimal

Future Directions

Research Priorities

Structural studies: High-resolution ATP13A2 structure to guide drug design

Biomarker validation: Clinical validation of pharmacodynamic markers

Delivery optimization: Next-generation AAV vectors with improved CNS targeting

Combination therapy: Rational combinations with other PD therapeutics

Unanswered Questions

Residual activity: Can missense mutants be pharmacologically enhanced?
Dosage regimen: Single vs. multiple administrations
Patient selection: Which patients will benefit most?
Biomarker correlates: Which biomarkers predict clinical response?

[ATP13A2 (PARK9) Pathway in Parkinson's Disease](/mechanisms/atp13a2-park9-pathway) — Mechanism of disease
[Kufor-Rakeb Syndrome](/diseases/kufor-rakeb-syndrome) — ATP13A2-associated disorder
[Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway) — Protein clearance mechanisms
[GBA Gene Therapy for Parkinson's Disease](/therapeutics/gba-gene-therapy) — Related lysosomal therapy
[Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons) — Converging pathways

References

[Ramirez et al., ATP13A2 mutations cause KRS (2006)](https://pubmed.ncbi.nlm.nih.gov/16583102/)

[Schneider et al., ATP13A2 mutations cause neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20074047/)

[Usenovic et al., ATP13A2 loss leads to lysosomal dysfunction (2012)](https://pubmed.ncbi.nlm.nih.gov/22425991/)

[Dehay et al., Lysosomal impairment in PD (2013)](https://pubmed.ncbi.nlm.nih.gov/23560208/)

[Wallings et al., Lysosomal function in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31310496/)

[Sorensen Madsen et al., ATP13A2 is a manganese transporter (2018)](https://pubmed.ncbi.nlm.nih.gov/29654278/)

[Kühlbrandt et al., Structure of P5-ATPases (2004)](https://pubmed.ncbi.nlm.nih.gov/15592455/)

[Rimon et al., Lysosomal copper accumulation (2020)](https://pubmed.ncbi.nlm.nih.gov/32156234/)

[Bento et al., ATP13A2 modulates iron metabolism (2016)](https://pubmed.ncbi.nlm.nih.gov/26873108/)

[Matsui et al., ATP13A2 deficiency in mouse model (2016)](https://pubmed.ncbi.nlm.nih.gov/27746571/)

[Yang et al., ATP13A2 and lysosomal iron (2020)](https://pubmed.ncbi.nlm.nih.gov/32350112/)

[Park et al., ATP13A2-mediated metal transport (2017)](https://pubmed.ncbi.nlm.nih.gov/28632479/)

[Abeliovich et al., Trafficking defects in PD (2016)](https://pubmed.ncbi.nlm.nih.gov/26786337/)

[Sancandi et al., AAV-mediated gene therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/31772706/)

[O'Hara et al., Biomarkers for ATP13A2 (2020)](https://pubmed.ncbi.nlm.nih.gov/32084723/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — 0.64 · Target: CSGA
[Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — 0.59 · Target: HTT, DMPK, repeat-containing transcripts
[Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — 0.64 · Target: HDAC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — 0.72 · Target: G3BP1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-atp13a2-therapy-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-atp13a2-therapy-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2a46914ba715
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-atp13a2-therapy-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

135

Outgoing

175

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ATP13A2 (PARK9) Targeting for Parkinson's Disease

ATP13A2 (PARK9) Targeting for Parkinson's Disease

Overview

ATP13A2 (PARK9) Targeting for Parkinson's Disease

Overview

Scientific Rationale

ATP13A2 Biology

Normal Function

In Disease

Therapeutic Rationale

Therapeutic Approaches

Gene Therapy

AAV-Mediated ATP13A2 Delivery

Challenges and Solutions

Clinical Development

Small Molecule Approaches

ATP13A2 Activators

Autophagy Induction

Metal Homeostasis Modulators

Protein Folding Correctors

Combination Therapies

Drug Development Pipeline

Current Programs

Clinical Status

Biomarkers for Therapeutic Development

Pharmacodynamic Biomarkers

Patient Selection Biomarkers

Disease Progression Markers

Animal Models

Genetic Models

Key Findings from Models

Comparison with GBA Gene Therapy

Challenges and Considerations

Delivery Challenges

Safety Considerations

Regulatory Considerations

Future Directions

Research Priorities

Unanswered Questions

Cross-Linking to Related Pages

References

Related Hypotheses

💬 Discussion